Figures computed from official regulatory filings — .
Analysttarget 1.5 USD (+290%)
Ownershipinsiders 1.24% · institutions 4.07% · short 2.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for KALA BIO, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
34 buys80 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Lazar David E. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lazar David E. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Bazemore Todd | Sell | $39.6K | SEC |
| Reumuth Mary | Sell | $26.8K | Unusual size | SEC |
| Reumuth Mary | Sell | $792.9 | SEC |
| Kharabi Darius | Sell | $17.3K | SEC |
| Brazzell Romulus K | Sell | $38.8K | Unusual size | SEC |
| Iwicki Mark Ttrack record | Sell | $125.5K | Unusual size | SEC |
| BAKER JULIANtrack record | Sell | $638.9K | SEC |
| BAKER JULIANtrack record | Sell | $69.9K | SEC |
| BAKER JULIANtrack record | Sell | $34.2K | SEC |
| BAKER JULIANtrack record | Sell | $312.7K | SEC |
| Bazemore Todd | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bazemore Todd | Sell | $16.3K | SEC |
| Reumuth Mary | Sell | $14.6K | SEC |
| Kharabi Darius | Sell | $18.1K | SEC |
| Iwicki Mark Ttrack record | Sell | $53K | SEC |
| Brazzell Romulus K | Sell | $21.1K | SEC |
| Farid Marjan | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| KOVEN ANDREW I | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Myers C. Daniel | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rosen Howard B | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PERRY GREGORY D | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Myers C. Daniel | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rosen Howard B | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |